Emerging target families: Intractable targets

Handbook of Experimental Pharmacology

Volumn 232, Issue , 2016, Pages 43-58

  Knapp, Stefan ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Druggability; Epigenetic reader domains; Phosphatases; Protein interaction inhibitors; RAS; Structure based design

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; BROMODOMAIN INHIBITOR; GUANOSINE TRIPHOSPHATASE; LONAFARNIB; NSC 87877; OICR 9429; PACLITAXEL; PHOSPHATASE; PROTEIN MDM2; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE 1B; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE SHP 2; PROTEIN TYROSINE PHOSPHATASE SHP 2 INHIBITOR; RAPAMYCIN; RAS PROTEIN; TIPIFARNIB; TRODUSQUEMINE; UNC 1215; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; DRUG ACTIVITY; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUGGABILITY; ENZYME INHIBITION; EPIGENETICS; HUMAN; IC50; IN VIVO STUDY; LIPOPHILICITY; MOLECULAR WEIGHT; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; DRUG DEVELOPMENT; MOLECULARLY TARGETED THERAPY;

ANIMALS; BINDING SITES; DRUG DISCOVERY; GTP PHOSPHOHYDROLASES; HUMANS; MOLECULAR TARGETED THERAPY; PHOSPHORIC MONOESTER HYDROLASES;

EID: 84962743618     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/164_2015_28     Document Type: Chapter

References (67)

1. Adachi K, Hikawa H, Hamada M, Endoh J.-I, Ishibuchi S, Fujie N, Tanaka M, Sugahara K, Oshita K, Murata M (2006) Preparation of thienotriazolodiazepine compounds having an action of inhibiting the CD28 costimulatory signal in T cell, Mitsubishi Pharma Corporation, Japan, pp 240
2. Alonso A, Sasin J, Bottini N, Friedberg I, Friedberg I, Osterman A, Godzik A, Hunter T, Dixon J, Mustelin T (2004) Protein tyrosine phosphatases in the human genome. Cell 117(6):699-711
3. Barr AJ (2010) Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development. Future Med Chem 2(10):1563-1576
4. Barr AJ, Ugochukwu E, Lee WH, King ON, Filippakopoulos P, Alfano I, Savitsky P, Burgess-Brown NA, Muller S, Knapp S (2009) Large-scale structural analysis of the classical human protein tyrosine phosphatome. Cell 136(2):352-363
5. Bos JL, Rehmann H, Wittinghofer A (2007) GEFs and GAPs: critical elements in the control of small G proteins. Cell 129(5):865-877
6. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP (2009) Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 9(12):862-873
7. Buhrman G, O'Connor C, Zerbe B, Kearney BM, Napoleon R, Kovrigina EA, Vajda S, Kozakov D, Kovrigin EL, Mattos C (2011) Analysis of binding site hot spots on the surface of Ras GTPase. J Mol Biol 413(4):773-789
8. Chan G, Kalaitzidis D, Neel BG (2008) The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev 27(2):179-192
9. Cheng AC, Coleman RG, Smyth KT, Cao Q, Soulard P, Caffrey DR, Salzberg AC, Huang ES (2007) Structure-based maximal affinity model predicts small-molecule druggability. Nat Biotechnol 25(1):71-75
10. Chung CW, Coste H, White JH, Mirguet O, Wilde J, Gosmini RL, Delves C, Magny SM, Woodward R, Hughes SA et al (2011) Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J Med Chem 54(11):3827-3838
11. Ciceri P, Muller S, O'Mahony A, Fedorov O, Filippakopoulos P, Hunt JP, Lasater EA, Pallares G, Picaud S, Wells C et al (2014) Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nat Chem Biol 10(4):305-312
12. Congreve M, Carr R, Murray C, Jhoti H (2003) A 'rule of three' for fragment-based lead discovery? Drug Discov Today 8(19):876-877
13. Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ (2014) Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov 13(11):828-851
14. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, Robson SC, Chung CW, Hopf C, Savitski MM et al (2011) Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478(7370):529-533
15. Elchebly M, Payette P, Michaliszyn E, Cromlish W, Collins S, Loy AL, Normandin D, Cheng A, Himms-Hagen J, Chan CC et al (1999) Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 283(5407):1544-1548
16. Ember SW, Zhu JY, Olesen SH, Martin MP, Becker A, Berndt N, Georg GI, Schonbrunn E (2014) Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors. ACS Chem Biol 9(5):1160-1171
17. Filippakopoulos P, Knapp S (2014) Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov 13(5):337-356
18. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I et al (2010) Selective inhibition of BET bromodomains. Nature 468 (7327):1067-1073
19. Filippakopoulos P, Picaud S, Fedorov O, Keller M, Wrobel M, Morgenstern O, Bracher F, Knapp S (2012) Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family. Bioorg Med Chem 20(6):1878-1886
20. Fish PV, Filippakopoulos P, Bish G, Brennan PE, Bunnage ME, Cook AS, Federov O, Gerstenberger BS, Jones H, Knapp S et al (2012) Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragmentderived hit. J Med Chem 55(22):9831-9837
21. Graves B, Thompson T, Xia M, Janson C, Lukacs C, Deo D, Di Lello P, Fry D, Garvie C, Huang KS et al (2012) Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization. Proc Natl Acad Sci U S A 109(29):11788-11793
22. Hajduk PJ, Huth JR, Fesik SW (2005) Druggability indices for protein targets derived from NMR-based screening data. J Med Chem 48(7):2518-2525
23. Halgren TA (2009) Identifying and characterizing binding sites and assessing druggability. J Chem Inf Model 49(2):377-389
24. Hay DA, Fedorov O, Martin S, Singleton DC, Tallant C, Wells C, Picaud S, Philpott M, Monteiro OP, Rogers CM et al (2014) Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains. J Am Chem Soc 136(26):9308-9319
25. Herold JM, Ingerman LA, Gao C, Frye SV (2011a) Drug discovery toward antagonists of methyllysine binding proteins. Curr Chem Genomics 5:51-61
26. Herold JM, Wigle TJ, Norris JL, Lam R, Korboukh VK, Gao C, Ingerman LA, Kireev DB, Senisterra G, Vedadi M et al (2011b) Small-molecule ligands of methyl-lysine binding proteins. J Med Chem 54(7):2504-2511
27. Hewings DS, Wang M, Philpott M, Fedorov O, Uttarkar S, Filippakopoulos P, Picaud S, Vuppusetty C, Marsden B, Knapp S et al (2011) 3,5-Dimethylisoxazoles act as acetyl-lysinemimetic bromodomain ligands. J Med Chem 54(19):6761-6770
28. Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Shoelson SE (1998) Crystal structure of the tyrosine phosphatase SHP-2. Cell 92(4):441-450
29. Hopkins AL, Groom CR (2002) The druggable genome. Nat Rev Drug Discov 1(9):727-730
30. James LI, Korboukh VK, Krichevsky L, Baughman BM, Herold JM, Norris JL, Jin J, Kireev DB, Janzen WP, Arrowsmith CH et al (2013a) Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3. J Med Chem 56(18):7358-7371
31. James LI, Barsyte-Lovejoy D, Zhong N, Krichevsky L, Korboukh VK, Herold JM, MacNevin CJ, Norris JL, Sagum CA, Tempel W et al (2013b) Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain. Nat Chem Biol 9(3):184-191
32. Julien SG, Dube N, Read M, Penney J, Paquet M, Han Y, Kennedy BP, Muller WJ, Tremblay ML (2007) Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis. Nat Genet 39(3):338-346
33. Karaguni IM, Herter P, Debruyne P, Chtarbova S, Kasprzynski A, Herbrand U, Ahmadian MR, Glusenkamp KH, Winde G, MareelMet al (2002) The new sulindac derivative IND 12 reverses Ras-induced cell transformation. Cancer Res 62(6):1718-1723
34. Karnoub AE, Weinberg RA (2008) Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 9 (7):517-531
35. Keller TH, Pichota A, Yin Z (2006) A practical view of 'druggability'. Curr Opin Chem Biol 10 (4):357-361
36. Knapp S, Weinmann H (2013) Small-molecule modulators for epigenetics targets. ChemMedChem 8(11):1885-1891
37. Krishnan N, Koveal D, Miller DH, Xue B, Akshinthala SD, Kragelj J, Jensen MR, Gauss CM, Page R, Blackledge M et al (2014) Targeting the disordered C terminus of PTP1B with an allosteric inhibitor. Nat Chem Biol 10(7):558-566
38. Lantz KA, Hart SG, Planey SL, Roitman MF, Ruiz-White IA, Wolfe HR, McLane MP (2010) Inhibition of PTP1B by trodusquemine (MSI-1436) causes fat-specific weight loss in dietinduced obese mice. Obesity (Silver Spring) 18(8):1516-1523
39. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46(1-3):3-26
40. Matzuk MM, McKeown MR, Filippakopoulos P, Li Q, Ma L, Agno JE, Lemieux ME, Picaud S, Yu RN, Qi J et al (2012) Small-molecule inhibition of BRDT for male contraception. Cell 150 (4):673-684
41. Maurer T, Garrenton LS, Oh A, Pitts K, Anderson DJ, Skelton NJ, Fauber BP, Pan B, Malek S, Stokoe D et al (2012) Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc Natl Acad Sci U S A 109(14):5299-5304
42. Miyoshi S, Ooike S, Iwata K, Hikawa H, Sugaraha K (2009) Antitumor agent. International patent WO/2009/084693. Mitsubishi Tanabe Pharma, Japan, pp 1-37
43. Muller S, Filippakopoulos P, Knapp S (2011) Bromodomains as therapeutic targets. Expert Rev Mol Med 13, e29
44. Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung CW, Chandwani R, Marazzi I, Wilson P, Coste H et al (2010) Suppression of inflammation by a synthetic histone mimic. Nature 468(7327):1119-1123
45. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM (2013) K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503(7477):548-551
46. Overington JP, Al-Lazikani B, Hopkins AL (2006) How many drug targets are there? Nat Rev Drug Discov 5(12):993-996
47. Picaud S, Da Costa D, Thanasopoulou A, Filippakopoulos P, Fish PV, Philpott M, Fedorov O, Brennan P, Bunnage ME, Owen DR et al (2013) PFI-1, a highly selective protein interaction inhibitor, targeting BET bromodomains. Cancer Res 73(11):3336-3346
48. Rask-Andersen M, Almen MS, Schioth HB (2011) Trends in the exploitation of novel drug targets. Nat Rev Drug Discov 10(8):579-590
49. Salmeen A, Andersen JN, Myers MP, Tonks NK, Barford D (2000) Molecular basis for the dephosphorylation of the activation segment of the insulin receptor by protein tyrosine phosphatase 1B. Mol Cell 6(6):1401-1412
50. Santiago C, Nguyen K, Schapira M (2011) Druggability of methyl-lysine binding sites. J Comput Aided Mol Des 25(12):1171-1178
51. Shen K, Keng YF, Wu L, Guo XL, Lawrence DS, Zhang ZY (2001) Acquisition of a specific and potent PTP1B inhibitor from a novel combinatorial library and screening procedure. J Biol Chem 276(50):47311-47319
52. Sheridan RP, Maiorov VN, Holloway MK, Cornell WD, Gao YD (2010) Drug-like density: a method of quantifying the "bindability" of a protein target based on a very large set of pockets and drug-like ligands from the Protein Data Bank. J Chem Inf Model 50(11):2029-2040
53. Shultz LD, Rajan TV, Greiner DL (1997) Severe defects in immunity and hematopoiesis caused by SHP-1 protein-tyrosine-phosphatase deficiency. Trends Biotechnol 15(8):302-307
54. Southan C, Boppana K, Jagarlapudi SA, Muresan S (2011) Analysis of in vitro bioactivity data extracted from drug discovery literature and patents: ranking 1654 human protein targets by assayed compounds and molecular scaffolds. J Cheminform 3(1):14
55. Sun Q, Burke JP, Phan J, Burns MC, Olejniczak ET, Waterson AG, Lee T, Rossanese OW, Fesik SW (2012) Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew Chem Int Ed Engl 51(25):6140-6143
56. Vassilev LT (2007) MDM2 inhibitors for cancer therapy. Trends Mol Med 13(1):23-31
57. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45(12):2615-2623
58. Vidler LR, Brown N, Knapp S, Hoelder S (2012) Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites. J Med Chem 55(17):7346-7359
59. Vidler LR, Filippakopoulos P, Fedorov O, Picaud S, Martin S, Tomsett M, Woodward H, Brown N, Knapp S, Hoelder S (2013) Discovery of novel small-molecule inhibitors of BRD4 using structure-based virtual screening. J Med Chem 56(20):8073-8088
60. Wang W, Fang G, Rudolph J (2012) Ras inhibition via direct Ras binding-is there a path forward? Bioorg Med Chem Lett 22(18):5766-5776
61. Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, Catino JJ, Bishop WR, Pai JK (1997) K-and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 272(22):14459-14464
62. Wiesmann C, Barr KJ, Kung J, Zhu J, Erlanson DA, Shen W, Fahr BJ, Zhong M, Taylor L, Randal M et al (2004) Allosteric inhibition of protein tyrosine phosphatase 1B. Nat Struct Mol Biol 11 (8):730-737
63. Xu R, Yu Y, Zheng S, Zhao X, Dong Q, He Z, Liang Y, Lu Q, Fang Y, Gan X et al (2005) Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia. Blood 106(9):3142-3149
64. You-Ten KE, Muise ES, Itie A, Michaliszyn E, Wagner J, Jothy S, Lapp WS, Tremblay ML (1997) Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatase-deficient mice. J Exp Med 186(5):683-693
65. Zeng LF, Zhang RY, Yu ZH, Li S, Wu L, Gunawan AM, Lane BS, Mali RS, Li X, Chan RJ et al (2014) Therapeutic potential of targeting the oncogenic SHP2 phosphatase. J Med Chem 57(15):6594-6609
66. Zhang G, Liu R, Zhong Y, Plotnikov AN, Zhang W, Zeng L, Rusinova E, Gerona-Nevarro G, Moshkina N, Joshua J et al (2012) Down-regulation of NF-kappaB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition. J Biol Chem 287(34):28840-28851
67. Zhou X, Coad J, Ducatman B, Agazie YM (2008) SHP2 is up-regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis. Histopathology 53(4):389-402